Dynamic Contrast-Enhanced Magnetic Resonance Imaging–Derived kep as a Potential Biomarker of Matrix Metalloproteinase 9 Expression in Patients With Glioblastoma Multiforme

Abstract

The association of kep and MMP-9 expression with survival suggests that kep may be used as imaging biomarker of GBM progression and its prognostication.

Assessment of blood–brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review

“…Information regarding patient age was not provided in seven of the 53 studies (Li et al, 2000; Li et al, 2012; Sourbron et al, 2009; Larsson et al, 1990; Aksoy et al, 2013; Miyati et al, 1997; Awasthi et al, 2012). A further seven publications stated only the age range of the study subjects (Awasthi et al, 2012; Haris et al, 2008b; Roberts et al, 2000; Vidarsson et al, 2009; Bagher-Ebadian et al, 2012; Kassner et al, 2005; Manuchehri et al, 2007).…”

“…A further seven publications stated only the age range of the study subjects (Awasthi et al, 2012; Haris et al, 2008b; Roberts et al, 2000; Vidarsson et al, 2009; Bagher-Ebadian et al, 2012; Kassner et al, 2005; Manuchehri et al, 2007). Mean age as stated in the remaining 39 human studies was highly dependent on the studied pathology, ranging between 9 years (Thompson et al, 2012) (pediatric brain tumors) and 74 years (Wang et al, 2006) (mild cognitive impairment).…”

“…The pathology most studied in humans was intracranial neoplasms (30 publications, 716/1564 subjects), including primary brain tumors and brain metastases (Li et al, 2012; Sourbron et al, 2009; Larsson et al, 2009; Larsson et al, 1990; Haris et al, 2008a,c; Thompson et al, 2012; Miyati et al, 1997; Awasthi et al, 2012; Roberts et al, 2000; Bagher-Ebadian et al, 2012; Manuchehri et al, 2007; Cao et al, 2009; Cha et al, 2006; Chu et al, 2012; Harrer et al, 2004; Ludemann et al, 2002; Lüdemann et al, 2009; Lüdemann et al, 2000; Mills et al, 2009; Provenzale et al, 2006; Zhu et al, 2000; Ferl et al, 2010; Jia et al, 2013; Larsen et al, 2013; Wilkinson et al, 2006; Zhang et al, 2012). Eleven studies investigated changes in BBB integrity caused by stroke and/or cerebrovascular disease (Kassner et al, 2009; Wardlaw et al, 2008; Wardlaw et al, 2009; Topakian et al, 2010; Armitage et al, 2011; Aksoy et al, 2013; Vidarsson et al, 2009; Kassner et al, 2005; Thornhill et al, 2010; Taheri et al, 2011a,b) with a total of 482/1564 subjects.…”

Schisandrin B suppresses glioma cell metastasis mediated by inhibition of mTOR/MMP-9 signal pathway

“…Thus, the degradation of the extracellular matrix mediated by proteases, such as matrix metallo proteinases (MMPs) allows glioma migration [13]. Matrix metalloproteinase-9 (MMP-9) is highly expressed in human GBM tissue [4,24] and was reported to be associated with slightly shorter overall survival in glioblastoma patients [5]. While cellular level of MMP-9 is highly regulated by mTOR [9].…”

T1-Weighted Dynamic Contrast-Enhanced MR Evaluation of Different Stages of Neurocysticercosis and Its Relationship with Serum MMP-9 Expression

“…k ep has been shown to be the best parameter for BBB breakdown in many neoplastic and infective conditions. 6,19,20 We found k ep as the best parameter to measure the BBB in different stages of NCC and showed a significant difference among the 3 clinically symptomatic stages: highest in the colloidal stage and lowest in the calcified stage (Table 1). Its strong and significant positive correlation with serum MMP-9 levels in the individual stage as well as when pooled together suggests that it may be used as an image biomarker of BBB permeability in different stages of NCC (Fig 5).…”